The "Nucleic Acid Therapeutics CDMO Market Size, Share & Trends Analysis, 2024-2030" report has been added to ...

Morgan Stanley analyst Michael Ulz reiterated a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target ...

Analyst Gena Wang of Barclays maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), retaining the price target of ...

On Thursday, Sarepta Therapeutics Inc (SRPT) stock saw a modest uptick, ending the day at $122.41 which represents a slight increase of $4.42 or 3.75% from the prior close of $117.99. The stock opened ...

Since the FDA cleared Sarepta Thereapeutics' gene therapy for nearly all people with Duchenne, its stock price has tanked.

As of the latest trading close, SRPT, a Healthcare sector stock, is trading -30.90% below its 52-week high but remains 116.69% above its 52-week low. The Average True Range (ATR) (14 days) of 3.67 ...

Recent Transaction Overview On September 30, 2024, Ikarian Capital, LLC (Trades, Portfolio) made a significant adjustment to ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Capricor Therapeutics (NASDAQ:CAPR) stock rose 5% in midday trading Friday after the company reported positive long-term data ...

Originally published in Quest Diagnostics' 2023 Corporate Responsibility Report We continued to grow access to and ...

Check the time stamp on this data. Updated AI-Generated Signals for Sarepta Therapeutics Inc. (SRPT) available here: SRPT.